Univar Solutions B.V.

Wilson’s Disease

Clinical research activity is centered on Wilson’s disease, with interest in the management of copper metabolism disorders and the biochemical markers used to monitor treatment response.

  • Hepatic copper accumulation
  • Neurologic and systemic manifestations
  • Copper balance assessment

The sponsor’s research focus includes therapeutic approaches intended to reduce excess copper and support ongoing disease control in affected patients.

Pharmacokinetics and Pharmacodynamics

Another key area of interest is pharmacokinetic and pharmacodynamic evaluation, particularly the relationship between treatment exposure and biological response in Wilson’s disease.

  • Exposure-response relationships
  • Drug disposition
  • Biomarker-linked response

Research activity is directed toward understanding how treatment levels relate to changes in copper markers and patient-specific response patterns.

Copper Biomarkers

The sponsor shows clear interest in biomarker-based assessment of treatment effects, including measures reflecting circulating and excreted copper burden.

  • 24-hour urinary copper excretion
  • Serum copper
  • Ceruloplasmin
  • Non-ceruloplasmin bound copper

This area of research supports clinical evaluation of disease activity and treatment-related changes in copper homeostasis.

Patient Characteristics and Individual Response

Research also extends to the influence of patient characteristics on treatment behavior, including factors that may affect clearance, distribution, and overall therapeutic response.

  • Apparent clearance
  • Apparent volume of distribution
  • Drug potency

This focus reflects interest in how individual clinical features may shape management of Wilson’s disease in routine care.

Oral Chelation Therapy

The therapeutic domain includes trientine dihydrochloride and other chelation-based approaches used to lower excess copper in Wilson’s disease.

  • Chelation therapy
  • Copper-removal treatment
  • Long-term disease management

Clinical interest is concentrated on treatment effects relevant to biochemical control and ongoing monitoring of copper overload.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Trientine Dihydrochloride (Cufence) to Evaluate Its Effects and Safety in Patients with Wilson’s Disease

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark France Germany Poland